This summer
the skin cancer foundation warned about the illegal one while the approved version cleared canada
In the same week in July 2026, two pieces of melanocortin news arrived from opposite directions. On July 7, the [Skin Cancer Foundation issued a formal warning against Melanotan II](https://www.skincancer.org/press/the-skin-cancer-foundation-issues-warning-regarding-melanotan-ii/), citing case reports linking the unapproved injectable to melanoma development, rapid mole changes, systemic toxicity, and muscle damage. The foundation described published medical literature accumulating to a threshold it could no longer ignore. Six days later, on July 13, [Clinuvel Pharmaceuticals announced that SCENESSE had received regulatory approval in Canada](https://www.clinuvel.com/2026/07/scenesse-approved-for-epp-in-canada-20260713/) — making Canada the fourth jurisdiction after the U.S., Europe, and Australia to approve afamelanotide, the compound Clinuvel describes as the world's first systemic photoprotective drug. A [Drug Topics investigation from August 3](https://www.drugtopics.com/view/the-vacation-peptide-raises-new-alarms-across-pharmacy) put a finer point on what the summer had produced: TikTok banned the melanotan hashtags, sellers migrated to unbranded packaging, urologists started seeing emergency presentations including a 22-hour priapism case, and Health Canada joined Australia's TGA in active enforcement. Searches for melanotan are running 22% above seasonal trend in October 2026. Most of those people are not asking about erythropoietic protoporphyria.
The molecule
afamelanotide hits mc1r — the same receptor as the underground version, for a completely different disease
Both afamelanotide and the underground Melanotan II compounds activate the melanocortin-1 receptor — the MC1R pathway that tells skin cells to produce eumelanin, the darkening pigment. In that narrow pharmacological sense they are cousins. Afamelanotide is a 13-amino-acid linear peptide, structurally derived from alpha-MSH, with substitutions at positions 4 and 7 that increase receptor potency and extend half-life beyond what the native hormone achieves. That engineered durability is what made it worth two decades of clinical development. The disease it treats — erythropoietic protoporphyria — is a defect in the FECH gene that causes protoporphyrin IX to accumulate in red blood cells and plasma. When light hits that protoporphyrin, it generates reactive oxygen species directly in the skin: not a sunburn, but a burning, excruciating phototoxic reaction that can last hours and leaves no visible mark that other people can see. Sustained MC1R activation through afamelanotide increases basal melanin in the epidermis, which attenuates how deeply UV light penetrates and reduces the light-triggered protoporphyrin reaction. [The PubMed literature on afamelanotide in EPP](https://pubmed.ncbi.nlm.nih.gov/?term=afamelanotide+erythropoietic+protoporphyria) documents this mechanism arc across two decades of clinical investigation.
The pitch
the internet sells it as the barbie drug — the reality is priapism cases and mole changes
The underground Melanotan II story has almost nothing to do with EPP patients. The pitch is cosmetic and recreational: a darker tan without sun exposure, a tool for bodybuilding competition prep, a shortcut for people who do not tan naturally or deeply enough to suit aesthetic goals. The compound is sold as a grey-market product in unbranded vials, often misrepresented as vitamins to sidestep detection. The August Drug Topics investigation found average users nearly 40 years old, male-dominated, and introduced through gym or bodybuilding networks — a profile that overlaps with the same community driving demand for unapproved GH-axis peptides on the same supply channels. What gets left out of the pitch: the changes in moles and pigmented lesions documented in case reports, which make skin cancer surveillance harder; the priapism cases appearing in urology emergency departments; the reports of possible renal infarction; and the Australian TGA and Health Canada enforcement actions against domestic sellers. TikTok banned the hashtags. Sellers promptly stopped using the hashtags. That is the regulatory gap that the Skin Cancer Foundation warning was designed to address — and that no platform-level enforcement has closed.
What the data says
the epp trials are real, the vitiligo program just got ema protocol approval, and tanning has zero controlled studies
Afamelanotide's clinical record is the opposite of Melanotan II's. The pivotal CLINASE trial — a randomized, double-blind, placebo-controlled study across European EPP centers — showed that afamelanotide meaningfully extended patients' pain-free time in sunlight compared with placebo. A separate Phase III trial conducted in the United States replicated the finding. Those results supported the FDA's 2019 approval of SCENESSE and the European and Australian approvals that preceded it. [ClinicalTrials.gov records an active Clinuvel program](https://clinicaltrials.gov/search?term=afamelanotide) now targeting vitiligo — the CUV105 global trial with topline data expected by December 2026, and Phase III CUV107 scheduled to start in November 2026 following European Medicines Agency protocol approval. That is an expansion of a legitimate drug development program into a second indication. The underground Melanotan II population has no equivalent data: no Phase II, no randomized placebo control, no pre-specified endpoints, no pharmacokinetics for subcutaneous injection in recreationally active adults. What exists instead are case reports in dermatology and urology journals, emerging from a population that self-doses from vials with no verified purity. [The FDA Orange Book lists the approved SCENESSE implant](https://www.accessdata.fda.gov/scripts/cder/ob/) — a 16 mg implant administered by a physician, not a self-injection from an online vial.
Approved — PeptideFactCheck stance
the approval is specific to epp; the underground market is something else entirely
Afamelanotide holds PeptideFactCheck's Approved evidence tier. The CLINASE and U.S. Phase III trials are real, the FDA label covers a specific and serious disease, and the clinical development history across four regulatory jurisdictions is one of the more rigorous in any niche peptide category. Approved does not mean available to everyone, safe for off-label injection, or evidence-backed for cosmetic tanning — it means a disease-specific medicine exists for patients with EPP who have no other approved photoprotective option. The Clinuvel Canada approval from July 13, 2026 expanded that option geographically. The Skin Cancer Foundation warning from July 7, 2026 drew a line the medical community has been circling for years: there is a legitimate melanocortin drug with a real regulatory record, and there is an unregulated black-market analog sold in unbranded vials with a growing case-report file on priapism, melanoma progression, and renal injury. The two are not the same compound, not the same indication, and not the same risk profile. Searches for melanotan in October 2026 are running at elevated levels. Most of those searches are landing on product pages, not clinical trials. That is the gap afamelanotide's approval history was never designed to close. Source trail before certainty.
Editorial boundary
What this page will not do
It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.